Anne Schuchat, MD served three decades at the Centers for Disease Control and Prevention, including two stints as Acting Director. She was the first Director of CDC’s National Center for Immunization and Respiratory Diseases and Chief Health Officer during the 2009 influenza pandemic. In the 1990’s, Schuchat spearheaded national guidelines for prevention of group B strep disease in newborns. Dr. Schuchat retired as a two-star Rear Admiral in the Commissioned Corps of the US Public Health Services. She is a graduate of Swarthmore College and Dartmouth Medical School and completed an internal medicine residency at NYU’s Manhattan VA Hospital before joining the CDC as an Epidemic Intelligence Service Officer, or disease detective. She was elected to the National Academy of Medicine and has received numerous awards, including the Fries Prize for Improving Health. Schuchat serves on the boards of Swarthmore College and GAVI, the Vaccine Alliance. Her book, The Epi Logs: A CDC Insider’s Story of Saving Lives, Fighting Fear, and Finding Joy (Johns Hopkins University Press) will be released in March 2027.
The traditional vaccine regulatory paradigm is facing an existential strain. As the threat landscape demands rapid deployment and platform technologies enable unprecedented development velocity, the industry is caught between the rigid certainty of traditional Phase 3 Randomized Controlled Trials (RCTs) and the agile necessity of alternative data pathways. This plenary panel confronts the friction point between classic clinical trial design and emergency health security. Leading regulatory architects, clinical trialists, and public health strategists will debate whether the future of vaccinology lies in demanding flawless, multi-year pre-licensure efficacy baselines, or in pivoting toward expedited approvals backed by aggressive, ultra-responsive adaptive clinical designs and post-market real-world surveillance.
Regulatory Frontline: MHRA / /WHO/ Health Canada
Public Health & Pandemics: CEPI / Gates Foundation
Industry R&D Pioneers: Sanofi / AstraZeneca / Janssen (former?)
Medcins Sans Frontiers Representative
WHO